Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Adenocarcinoma/drug therapy/pathology"'
Autor:
Al-Batran, Salah-Eddin, Homann, Nils, Pauligk, Claudia, Goetze, Thorsten O, Meiler, Johannes, Kasper, Stefan, Kopp, Hans-Georg, Mayer, Frank, Haag, Georg Martin, Luley, Kim, Lindig, Udo, Schmiegel, Wolff, Pohl, Michael, Stoehlmacher, Jan, Folprecht, Gunnar, Probst, Stephan, Prasnikar, Nicole, Fischbach, Wolfgang, Mahlberg, Rolf, Trojan, Jörg, Koenigsmann, Michael, Martens, Uwe M, Thuss-Patience, Peter, Egger, Matthias, Block, Andreas, Heinemann, Volker, Illerhaus, Gerald, Moehler, Markus, Schenk, Michael, Kullmann, Frank, Behringer, Dirk M, Heike, Michael, Pink, Daniel, Teschendorf, Christian, Löhr, Carmen, Bernhard, Helga, Schuch, Gunter, Rethwisch, Volker, von Weikersthal, Ludwig Fischer, Hartmann, Jörg T, Kneba, Michael, Daum, Severin, Schulmann, Karsten, Weniger, Jörg, Belle, Sebastian, Gaiser, Timo, Oduncu, Fuat S, Güntner, Martina, Hozaeel, Wael, Reichart, Alexander, Jäger, Elke, Kraus, Thomas, Moenig, Stefan Paul, Bechstein, Wolf O, Schuler, Martin, Schmalenberg, Harald, Hofheinz, Ralf D, FLOT4-AIO Investigators
Publikováno v:
The Lancet, Vol. 393, No 10184 (2019) pp. 1948-1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::0b9cf264bfe92e55766adcd35c21e6e4
https://archive-ouverte.unige.ch/unige:134616
https://archive-ouverte.unige.ch/unige:134616
Publikováno v:
Revue médicale suisse, Vol. 11, No 475 (2015) pp. 1103-1107
In incurable diseases, maintenance therapy aims to prolong the response achieved through induction. The goal is to delay disease progression, thus prolonging survival. Two maintenance modalities are used. The first, called continuation maintenance, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::4fb4627b891e2b59cb732129c001142c
https://archive-ouverte.unige.ch/unige:90182
https://archive-ouverte.unige.ch/unige:90182
Publikováno v:
World Journal of Surgical Oncology
World Journal of Surgical Oncology, Vol 8, Iss 1, p 23 (2010)
World Journal of Surgical Oncology, Vol 8, Iss 1, p 23 (2010)
Background: This study reviewed the impact of pre-operative chemoradiotherapy or post-operative chemotherapy and/or radiotherapy on total mesorectal excision (TME) for ultralow rectal cancers that required either low anterior resection with peranal c
Publikováno v:
Cancer treatment reviews
Aim: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the literature. Patients and met
Autor:
Rob Glynne-Jones, Rudolf Maibach, Kaspar Rufibach, Piercarlo Saletti, Martin Leslie, Stephen Falk, Arnaud Roth, Dieter Köberle, M. Wernli, Nicola Fazio, Lukas Widmer, Markus Borner, Filippo de Braud, Matthew T. Seymour, Jürg Bernhard, Roger Stupp
Publikováno v:
Journal of Clinical Oncology, Vol. 25, No 22 (2007) pp. 3217-23
Purpose This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 94 (4
British Journal of Cancer, 94 (4
Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33
Autor:
Haralabos Kalofonos, Kardamakis, D., Bamias, A., Skarlos, D., Papakostas, P., Bafaloukos, D., Sakantamis, A., Pavlidis, N., Fountzilas, G.
Publikováno v:
Scopus-Elsevier
BACKGROUND: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied the toxicity profile of post
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::82b24143c53a968bfaeda22681328ce5
http://olympias.lib.uoi.gr/jspui/handle/123456789/24038
http://olympias.lib.uoi.gr/jspui/handle/123456789/24038
Autor:
Huguier, Michel, Barrier, Alain, Valinas, R., Flahault, Antoine, Adloff, M., Pezet, D., Jaeck, D., Millat, B.
Publikováno v:
Hepato-gastroenterology, Vol. 48, No 39 (2001) pp. 875-8
Phase II trials of combined 5 fluorouracil, leucovorin and cisplatin have demonstrated an 18-28% response rate in advanced pancreatic carcinomas. We investigated the effect of this chemotherapy regime on patients' survival.Patients included gave info
To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::e054fb52143724a18c7ab886fb38e0aa
http://olympias.lib.uoi.gr/jspui/handle/123456789/19731
http://olympias.lib.uoi.gr/jspui/handle/123456789/19731
Growth and proliferation were studied of a transplantable mouse tumor, the adenocarcinoma EO 771 (Adca EO 771) growing in C 57 and in nude mice on the one hand, and of human tumors (renal cell and hypopharynx carcinoma) growing in nude mice on the ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::03cae676a3f7f8a7cfe6e58db63afa10
http://olympias.lib.uoi.gr/jspui/handle/123456789/21326
http://olympias.lib.uoi.gr/jspui/handle/123456789/21326